
Venture investor backing food and beverage technology companies, run by finance professionals and former food operators

Life science investor putting money into young oncology and genetic disease drug developers

DROIA Ventures is a specialist investor that puts money only into therapeutics for cancer and genetic disease, and it works worldwide. It says it backs young drug development companies that rely on novel science and fresh approaches to bring promising therapies to patients. Because it has its own team of drug development experts and biotech professionals, it can take an active part in each company from creation through to clinical proof of concept, and it describes its people as hands-on investors and entrepreneurs.
The firm measures success by real benefit to patients. A promising therapy, in its view, should change patient prognosis in a material way, judged by how severe the unmet medical need is and by how far the treatment improves on the expected standard of care. It invests only in companies whose technology platforms or scientific insight can address clinical problems that were previously unsolvable, and it wants a company to stand out for how its innovation turns into a clinical breakthrough, not just for the innovation itself. The team scouts for the best science and the best teams.
Whether it backs an existing company or starts a new one, the team takes part in development. Its members bring experience in disease biology, translational science, clinical development and company building, have created many companies from the ground up, and will take interim roles inside a company so it gets off the ground faster. A scientific arm, Droia Labs, validates novel ideas for young companies and provides laboratory facilities.
The portfolio covers several areas of science. In cancer and immune-oncology: Accent Therapeutics works on small molecule drugs in epitranscriptomics; Ambagon Therapeutics is developing first-in-class drugs that stabilize 14-3-3 protein complexes; Arcus Biosciences combines small molecules and antibodies against tumor-related immune suppression; Aura Biosciences develops tumor-targeted viral-like nanoparticles, with a lead product in trials against ocular melanoma; Cyteir Therapeutics pursues synthetic lethal therapies; Hummingbird Bioscience develops antibody-based drugs; Montis Biosciences targets the link between macrophages and tumor blood vessels; Octimet develops selective MET kinase inhibitors; PACT Pharma makes personalized T-cell therapies; Volastra Therapeutics targets chromosomal instability; and Tusk Therapeutics, which was acquired by Roche, built immune-modulating antibodies.
In genetic and neurological disease: Actio Biosciences works on proteins behind rare diseases; Alesta Therapeutics on kinase inhibitors for rare neuro-related diseases and cancer; Mahzi Therapeutics on rare neurodevelopmental disorders; Muna Therapeutics on brain-penetrant molecules for neurodegenerative conditions; QurAlis on amyotrophic lateral sclerosis; Vicinitas Therapeutics on stabilizing proteins that are wrongly degraded; and Vico Therapeutics on RNA-modulating treatments for rare neurological disorders. Cristal Therapeutics develops nanoparticle drug delivery, Frontier Medicines uses chemoproteomics and machine learning against hard-to-drug targets, and Highlight Therapeutics works on immune-stimulating nanocomplexes.
DROIA Ventures is a specialist investor in early drug development companies. It works worldwide and puts money only into therapies for cancer and genetic disease. Its in-house team of drug developers and biotech professionals takes an active part in the companies it backs, from their creation to clinical proof of concept.
It targets biotech companies whose technology or scientific insight can address clinical problems not solved before. It judges promise by how much a therapy could improve patient outcomes compared with the expected standard of care. Its portfolio spans the US and Europe.
Summary written by TrustList from the business's own published information, Nov 2026.
2 images - click to enlarge
Used it? Your experience helps other buyers decide.
Write a reviewNo questions yet. Be the first to ask about DROIA Ventures.
Similar listings buyers compare against this one.

Venture investor backing food and beverage technology companies, run by finance professionals and former food operators
New York venture capital firm making early and growth stage investments on the East Coast, mostly as co-investor

Healthcare venture firm investing in medical device, pharmaceutical and therapy companies with experienced management teams

New York boutique venture firm investing in growth-stage technology companies across several sectors

Austin-based evergreen venture firm investing in software, technology-enabled and life science companies

Impact-focused venture fund backing scalable businesses that tackle social and environmental problems

Corporate venture arm of the Volvo Group investing in startups that change transport and logistics

A venture capital firm backing founders at the pre-seed and seed stages across a range of industries
Everything here links back to the same verified catalogue. Pick your next stop.